Bank of New York Mellon Corp Takes $973,000 Position in Aptinyx Inc (NASDAQ:APTX)

Aptinyx logo Bank of New York Mellon Corp purchased a new stake in shares of Aptinyx Inc (NASDAQ:APTX) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 33,603 shares of the company’s stock, valued at approximately $973,000. Bank of New York Mellon Corp owned 0.10% of Aptinyx at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wells Fargo & Company MN purchased a new position in shares of Aptinyx during the third quarter valued at about $185,000. JPMorgan Chase & Co. increased its position in shares of Aptinyx by 8.1% during the third quarter. JPMorgan Chase & Co. now owns 169,408 shares of the company’s stock valued at $4,906,000 after buying an additional 12,708 shares during the period. Northern Trust Corp purchased a new position in shares of Aptinyx during the second quarter valued at about $304,000. Rhumbline Advisers purchased a new position in shares of Aptinyx during the third quarter valued at about $287,000. Finally, BlackRock Inc. purchased a new position in shares of Aptinyx during the second quarter valued at about $967,000. Institutional investors own 63.92% of the company’s stock.

In other news, CFO Ashish Khanna purchased 10,000 shares of the business’s stock in a transaction dated Friday, January 18th. The shares were purchased at an average price of $5.45 per share, for a total transaction of $54,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, Director Robert J. Hombach purchased 25,000 shares of the business’s stock in a transaction dated Friday, January 25th. The shares were purchased at an average price of $5.53 per share, for a total transaction of $138,250.00. The disclosure for this purchase can be found here . In the last quarter, insiders have bought 36,050 shares of company stock worth $198,284.

Shares of APTX opened at $4.17 on Wednesday. Aptinyx Inc has a fifty-two week low of $4.13 and a fifty-two week high of $32.25.

A number of brokerages have weighed in on APTX. BMO Capital Markets cut their price objective on shares of Aptinyx to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 18th. Cantor Fitzgerald restated a “buy” rating and issued a $40.00 price objective on shares of Aptinyx in a report on Wednesday, January 16th. Zacks Investment Research upgraded shares of Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Monday, January 21st. JPMorgan Chase & Co. cut shares of Aptinyx from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $30.00 to $8.00 in a report on Thursday, January 17th. Finally, Leerink Swann cut their price objective on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, January 17th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $18.80.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. Institutional Ownership by Quarter for Aptinyx (NASDAQ:APTX) Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *